Evolution of Continuous Chromatography: Moving Beyond Chiral Separations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evolution of Continuous Chromatography: Moving Beyond Chiral Separations
The author presents recent developments in simulated moving-bed chromatography in production of active pharmaceutical ingredients and intermediates. This article is part of a special issue on APIs.


Pharmaceutical Technology
pp. s22-s27


Figure 3: Comparison between traditional four-zone simulated moving-bed (SMB) and the modified SMB system for separations with large selectivity or increasing retention time. (FIGURE IS COURTESY OF THE AUTHOR)
SMB modifications for increased throughput. SMB provides a significant advantage over batch chromatography when the selectivity of the separation is rather low. In the case of high selectivity, batch chromatography may outperform SMB because of flow and operating pressure constraints. In an SMB unit, the flow rate in the first zone of columns pushes out the most retained product. For a long retention time, it takes a high flow rate to push everything out of the column before the column switch occurs. Because all the zones of the SMB are connected, if one zone is operated at a very high flow rate, then the other zones must be operated at a lower flow rate. This zone manipulation is necessary to manage operations below the maximum operating pressure of the system. As a result, the production rate is reduced. AFC developed a simple modification to the process (see Figure 3) that alleviates the pressure constraint by decoupling the first zone of the SMB from the other zones of the SMB unit (12). This additional zone allows for a rapid wash of the column with the mobile phase at maximum operating pressure without affecting the pressure in the other zone. As a result, the rest of the separation can be conducted at a higher flow rate and therefore at a higher throughput.

SMB for chiral separations and impurity removal. Ideally, racemic feeds only contain the two enantiomers. Unfortunately, in most cases, a few impurities that are closely related to the product also are present in the mixture. These impurities are usually either leftover starting material or side products from previous reactions. In either case, they might be difficult to remove during downstream processing without sacrificing yield. The chiral SMB separation can potentially be used to purify the product as the enantiomers are separated. Many publications describe the SMB process, but they rarely address impurities (6, 7, 13). If an impurity is present in the racemic product, it can potentially be doubled after the separation because approximately 50% of the mass of the feed is removed. Therefore, it is important to know the fate of the impurity during the SMB separation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here